Edition:
United States

Vascular Biogenics Ltd (VBLT.OQ)

VBLT.OQ on NASDAQ Stock Exchange Global Market

6.60USD
8 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$6.60
Open
$6.65
Day's High
$6.70
Day's Low
$6.55
Volume
13,363
Avg. Vol
53,095
52-wk High
$9.05
52-wk Low
$3.95

Summary

Name Age Since Current Position

Bennett Shapiro

76 2007 Non-Executive Independent Chairman of the Board

Dror Harats

59 2001 Chief Executive Officer, Director

Amos Ron

59 2011 Chief Financial Officer

Jacob George

49 2000 Chief Scientific Officer

Eyal Breitbart

47 2014 Vice President - Research and Operations

Erez Feige

41 2014 Vice President - Business Operations

Yael Cohen

51 2008 Vice President - Clinical Development

Naamit Sher

60 2006 Vice President - Drug Development and Regulatory Affairs

Ayelet Horn

43 2007 General Counsel, Company Secretary

Ruth Alon

65 2010 Non-Executive Director, Independent Director

Ruth Arnon

81 2007 Non-Executive Independent Director

Dan Gelvan

50 2005 Non-Executive Independent Director

Jecheskiel Gonczarowski

69 2001 Non-Executive Independent Director

Jide Zeitlin

53 2008 Non-Executive Independent Director

Biographies

Name Description

Bennett Shapiro

Dr. Bennett M. Shapiro M.D., is Non-Executive Independent Chairman of the Board of Vascular Biogenics Ltd. He has served on our board of directors since September 2004 and has served as Chairman since 2007. In addition to serving on our board of directors, Dr. Shapiro has served as a senior partner at Puretech Ventures, an innovation enterprise, since 2004, and as chairman since 2009, and is a consultant in the field of biotechnology. From 1990 to 2003, Dr. Shapiro served as executive vice president, Merck Research Laboratories. Prior to that, from 1970 to 1990, Dr. Shapiro was a professor of the Department of Biochemistry at the University of Washington and served as chairman from 1985 to 1990. Prior to joining the University of Washington, from 1965 to 1970 Dr. Shapiro served as a research associate, then section head, in the Laboratory of Biochemistry of the National Heart Institute of the U.S. National Institutes of Health. Dr. Shapiro also currently serves as an external director on the board of directors of Momenta Pharmaceuticals, various private companies and the Drugs for Neglected Diseases Initiative, an independent, non-profit development partnership. Dr. Shapiro previously served on the board of directors of Celera Corporation prior to its acquisition by Quest Diagnostics Inc. Dr. Shapiro received his B.S. in chemistry from Dickinson College and his M.D. from Jefferson Medical College. Dr. Shapiro has been a Guggenheim Fellow, a fellow of the Japan Society for the Promotion of Science and a visiting professor at the University of Nice.

Dror Harats

Prof. Dror Harats serves as Chief Executive Officer and Director of Vascular Biogenics Ltd since January 2001. He has founded the Company in 2000 and has served as its Chief Executive Officer since then. His work experience includes the following roles: Chairman of the Bert W. Strassburger Lipid Center at the Chaim Sheba Medical Center at Tel Hashomer Hospital and Chairman of its Institute Review Board, Professor of Medicine in the Departments of Internal Medicine and Biochemistry at the Sackler Faculty of Medicine at Tel-Aviv University, Visiting Scientist at Syntax Discovery Research and Observer on the board of directors of Art Healthcare Ltd. Prof. Harats holds a Doctorate of Medicine degree from Hadassah Medical School at the Hebrew University of Jerusalem and has conducted post-doctoral work at the University of California, San Francisco.

Amos Ron

Mr. Amos Ron is Chief Financial Officer of Vascular Biogenics Ltd. Prior to joining our company, from July 2008 to April 2011, Mr. Ron was the chief financial officer of Atlantium Technologies Ltd., a privately held start-up in the field of clean-tech. Prior to that, Mr. Ron served as the chief financial officer and chief operating officer of Medical Compression Systems, and prior to that, Mr. Ron served as the chief financial officer of Interpharm Laboratories Group, a wholly owned subsidiary of Serono S.A. Mr. Ron holds an M.Sc. (Honors) in Chemical Technology Management from the Hebrew University of Jerusalem, a B.Sc. in Business Administration, Empire State College (SUNY) (Jerusalem Branch) and a B.Sc. in Chemistry from the Hebrew University of Jerusalem.

Jacob George

Professor Jacob George is Chief Scientific Officer at VBL Therapeutics. Prof. George is a co-inventor of our Lecinoxoid platform technology. Prof. George also serves on the board of directors of, as well as an advisor to, Chemomab Ltd. Prof. George received his M.D. from the Technion School of Medicine, Israel. Prof. George is the chief of cardiology in the Kaplan Medical Center, Israel, and a full professor of cardiology at the Hebrew University of Jerusalem, Israel.

Eyal Breitbart

Dr. Eyal Breitbart Ph.D., is Vice President - Research and Operations of Vascular Biogenics Ltd. Prior to that, from 2006 to 2013, Dr. Breitbart served as our vice president, research. Dr. Breitbart holds a B.Sc., M.Sc. and Ph.D. from Bar-Ilan University, Israel, and completed a post-doctoral fellowship at Tufts University School of Medicine.

Erez Feige

Dr. Erez Feige is Vice President - Business Operations of Vascular Biogenics Ltd. Prior to that, from 2012 to 2014, Dr. Feige served as our director of business development and, from 2006 to 2012, Dr. Feige served as our head of biochemistry. Dr. Feige holds a B.Sc. and a Ph.D. from Bar-Ilan University, Israel and completed a post-doctoral fellowship at the Dana-Farber Cancer Institute and Harvard Medical School.

Yael Cohen

Dr. Yael Cohen M.D. is Vice President - Clinical Development of Vascular Biogenics Ltd. Prior to joining our company, Dr. Cohen served in various positions in Gamida Cell Ltd., Merck & Co. and Merck Research Labs, from 2000 to 2008. Dr. Cohen holds an M.D. from the Sackler Medical School at Tel Aviv University, Israel, and completed her residency in internal medicine at the Chaim Sheba Medical Center at Tel Hashomer, Israel, and a fellowship in hematology at the Rabin Medical Center, Petach Tikva, Israel. Dr. Cohen is a senior physician at the Hematology Department at the Sourasky Medical Center, Tel Aviv, Israel.

Naamit Sher

Dr. Naamit Sher Ph.D., is Vice President - Drug Development and Regulatory Affairs of Vascular Biogenics Ltd. Prior to joining our company, from 2005 to 2006, Dr. Sher was head of QC laboratories, operations division at Teva Pharmaceutical Industries Ltd. From 1992 to 2005, Dr. Sher acted as quality control/quality assurance director at InterPharm, a subsidiary of Ares-Serono. Dr. Sher holds a B.Sc., M.Sc. and Ph.D. from the Hebrew University of Jerusalem, Israel. She completed post-doctoral fellowships at each of the Hebrew University, Jerusalem, Israel, and Rutgers University.

Ayelet Horn

Adv. Ayelet Horn is General Counsel, Company Secretary of Vascular Biogenics Ltd. Horn has served as our general counsel since our inception in 2000, and has served as our company secretary since 2007. Adv. Horn holds an LL.B from Tel-Aviv University, Israel, and an M.B.A. from Herriot Watt University, Edinburgh, Scotland.

Ruth Alon

Ms. Ruth Alon is Non-Executive Independent Director of Vascular Biogenics Ltd. Since 1997, Ms. Alon has served as a general partner in Pitango Venture Capital. Prior to her tenure at Pitango, Ms. Alon held senior positions with Montgomery Securities from 1981 to 1987 and Kidder Peabody & Co. from 1987 to 1993, and managed her own independent consulting business in San Francisco in the medical devices industry from 1995 to 1996. Ms. Alon is the chairperson of Israel Life Science Industry, a not-for-profit organization representing the mutual goals of approximately 700 Israeli life science companies. Ms. Alon has a B.A. in Economics from the Hebrew University of Jerusalem, Israel, an M.B.A. from Boston University, and an M.S. from the Columbia University School of Physicians and Surgeons.

Ruth Arnon

Professor Ruth Arnon is Non-Executive Independent Director of Vascular Biogenics Ltd. Prof. Arnon is an immunologist with the Weizmann Institute of Science in Israel. Prof. Arnon joined the staff of the Weizmann Institute in 1960, and served as vice president of the Institute from 1988 to 1997. Prof. Arnon is a member of the Israel Academy of Sciences, and since 2010, has served as its president. Prof. Arnon is also an elected member of the European Molecular Biology Organization. She has served as president of the European Federation of Immunological Societies, and as secretary-general of the International Union of Immunological Societies. Her awards and honors include the Robert Koch Prize in Medical Sciences, Spain’s Jimenez Diaz Memorial Award, France’s Legion of Honor, the Hadassah World Organization’s Women of Distinction Award, the Wolf Prize for Medicine, the Rothschild Prize for Biology, and the Israel Prize. Prof. Arnon earned her M.Sc. in Chemistry from the Hebrew University, Jerusalem, Israel, and her Ph.D. from the Hebrew University.

Dan Gelvan

Dr. Dan J. Gelvan is Non-Executive Independent Director of Vascular Biogenics Ltd. Since 2005, Dr. Gelvan has served as the managing director-life sciences, Aurum Ventures M.K.I Ltd. Before joining Aurum Ventures, Dr. Gelvan was the chief executive and president of GammaCan International, Inc., a development-stage pharmaceutical company, from 2004 to 2005. From 2004 to 2008, Dr. Gelvan served as a member of the Israel National Committee on Biotechnology and, from 1997 to 2004, Dr. Gelvan served as the chief executive officer and president of Zetiq Technologies. From 1995 to 1997, Dr. Gelvan held a senior position in Clal (Israel) Ltd., an investment firm. Dr. Gelvan holds a B.A. and an M.A. in Economics from the Hebrew University of Jerusalem, Israel and a Ph.D. in Business Economics from Roskilde University in Denmark.

Jecheskiel Gonczarowski

Mr. Jecheskiel Gonczarowski is Non-Executive Independent Director of Vascular Biogenics Ltd. Since 2010, Mr. Gonczarowski has served as the chairman and chief executive officer of D.S.N.I. Investments Ltd., an Israeli based private family office, managing various local and international investments. Prior to that, Mr. Gonczarowski founded and co-managed Getter Group Ltd, a publicly traded company in Israel specializing in exclusive representation of leading international suppliers and brands, from 1982 to 2010. Mr. Gonczarowski also served on the board of directors of Rotshtein Realestate Ltd., a publicly traded company in Israel performing private and public construction in Israel. Mr. Gonczarowski studied economics, mathematics and business administration at the Hebrew University of Jerusalem, Israel.

Jide Zeitlin

Mr. Jide J. Zeitlin is Non-Executive Independent Director of Vascular Biogenics Ltd. Mr. Zeitlin is the founder and, since 2006, has served as the president of The Keffi Group Ltd., an investment firm. Mr. Zeitlin formerly served as an employee of The Goldman Sachs Group, Inc. from 1987 until December 2005 and as a partner from 1996 until 2005, where his career included a number of senior management positions including serving in the firm’s executive office. Mr. Zeitlin is Chairman Emeritus of the Board of Trustees at Amherst College and is a member of the Boards of the Harvard Business School Board of Dean’s Advisors, Teach for America, Nigeria Sovereign Investment Authority, Montefiore Medical Center, Playwrights Horizons, Common Ground Community, Doris Duke Charitable Foundation and Saint Ann’s School. He also serves on the board of directors of Affiliated Managers Group, Inc. and is the lead director of Coach, Inc. Mr. Zeitlin holds a B.A. in Economics and English from Amherst College and an M.B.A. from Harvard University.